Study of the bioequivalence of drugs for veterinary use «Avecardit» and «Vetmedin S» in the body of dogs
https://doi.org/10.32634/0869-8155-2024-383-6-33-38
Abstract
This article reflects the results of a pharmacokinetic comparison of the reproducible drug based on pimobendan «Avecardit» with the reference drug «Vetmedin S» when used in dogs. The experiment used a sequential study design. A group of experimental dogs was formed, consisting of 7 animals (6 main and 1 reserve animal). Blood sampling was carried out before administration and after 10, 20, 40 min; 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12 and 24 hours after drug administration. Key parameters assessed during the study: maximum concentration (Cmax) and time to reach it, area under the concentration-time curve (AUC) of the active substance of the drug in the blood serum of dogs. The article describes the main stages of the experiment, reagents and standard samples, the process of sample preparation of blood serum samples and HPLC-MS/MS analysis, and presents the results of a study of the bioequivalence of the drugs «Avecardit» and «Vetmedin S».
The time to reach the maximum concentration of pimobendan (Tmax) in the blood serum averaged 0.67–1 hour for the drug «Avecardit», 1–1.5 hours for the drug «Vetmedin S».
Maximum blood serum concentrations (Cmax) of pimobendan were in the range of 53,995–62,873 ng/ml for the study drug and 49,956–61,108 ng/ml for the reference drug. The 90% confidence intervals for the CmaxT/CmaxR and AUC0-tT/AUC0-tR ratios of pimobendan were within the range of 80–125%. The obtained results of the research work, from a scientific point of view, are a sufficient basis for recognizing the pharmacokinetic equivalence of the reproduced drug to the reference one.
About the Authors
V. V. GolovinRussian Federation
Vyacheslav Viktorovich Golovin, Candidate of Biological Sciences
3А Nagornaya Str., Moscow, 117186
S. V. Abramov
Russian Federation
Sergey Vladislavovich Abramov, Candidate of Veterinary Sciences
6 Rokossovskiy Str., Volgograd, 400131
A. V. Balyshev
Russian Federation
Andrey Vladimirovich Balyshev, Candidate of Biological Sciences
6 Rokossovskiy Str., Volgograd, 400131
P. P. Kochetkov
Russian Federation
Pavel Pavlovich Kochetkov, Head of the Laboratory
3А Nagornaya Str., Moscow, 117186
B. V. Violin
Russian Federation
Boris Viktorovich Violin, Candidate of Veterinary Sciences
24/1 Ryazansky Prospekt, Moscow, 109428
References
1. Gorlov I.F., Balyshev A.V., Starikov N.M., Abramov S.V., Golovin V.V. Comparative pharmacokinetic study of two drugs for veterinary use based on doxycycline Doxitart 500 and Misoxin ® in broilers. Veterinary medicine. 2023; (8): 46–49 (in Russian). https://doi.org/10.30896/0042-4846.2023.26.8.46-49
2. Ponamarev V.S., Lunegov A.M. Relevant bioequivalence study designs of medicinal products for veterinary use. Issues of legal regulation in veterinary medicine. 2021; (2): 81–84 (in Russian). https://doi.org/10.17238/issn2072-6023.2021.2.81
3. Yaichkov I.I. The features of researches of generic drugs. Medical.ethics. 2019; 7(1); 84–101 (in Russian). https://elibrary.ru/xfrvew
4. Goryachev D.V., Uvarova N.E. Evaluation of Bioequivalence of Generic Imatinib Products and Generic Tacrolimus Products Based on Indirect Comparison of the Results of Their Bioequivalence Studies. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2019; 9(3): 184–190 (in Russian). https://doi.org/10.30895/1991-2919-2019-9-3-184-190
5. Konovalova G.V., Lobova P.S., Gritsuk V.A., Morozova A.V., Tokar V.V. Specifics of planning and conducting preclinical studies of medicinal products for veterinary use Veterinary medicine. 2022; (2): 58–62 (in Russian). https://doi.org/10.30896/0042-4846.2022.25.2.58-62
6. Gerasimov S.V., Ponamarev V.S., Andreeva N.L., Lunegov A.M., Popova O.S. Analysis of regulatory documents regulating the requirements for conducting pre-clinical research of the veterinary drugs. Issues of legal regulation in veterinary medicine 2020; (3): 27–29 (in Russian). https://doi.org/10.17238/issn2072-6023.2020.3.27
7. Sergeev D.B. Analysis of cardiac pathologies in dogs. Agricultural science in the context of modernization and innovative development of the Russian agro-industrial complex. Collection of proceedings of the All-Russian scientific and methodological conference with international participation, dedicated to the 100th anniversary of higher agricultural education in the Ivanovo region. Ivanovo: Ivanovo State Agricultural Academy by academician D.K. Belyaev. 2018; 491–494 (in Russian). https://elibrary.ru/mpwalq
8. Saengklub N., Boonyarattanasoonthorn T., Kijtawornrat A., Chantasart D. Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs. Veterinary Sciences. 2022; 9(3): 141. https://doi.org/10.3390/vetsci9030141
9. Pichayapaiboon P. et.al. Pharmacodynamics and Pharmacokinetics of Injectable Pimobendan and Its Metabolite, O-Desmethyl-Pimobendan, in Healthy Dogs. Frontiers in Veterinary Science. 2021; 8: 656902. https://doi.org/10.3389/fvets.2021.656902
10. Sergeeva P.B., Sergeev D.B. Effect of increased dosages of pimobendan on dogs with dilated cardiomyopathy. Current issues of modern science: theory, methodology, practice, innovation: Collection of scientific articles based on the proceedings of the IV International Scientific and Practical Conference. Ufa: Vestnik nauki. 2020; 43–45 (in Russian). https://elibrary.ru/bmopor
11. Annikov V.V., Annikova L.V., Egunova A.V., Mikhalkin A.S., Pantyulin A.M., Shaikhrazieva E.Sh. Structure of the morbidity of dogs of the cardiovascular pathology in the southern part of Moscow region. Innovative technologies in science and education Collection of articles of the XII International scientific and practical conference. Penza: Nauka i Prosveshchenie. 2019; 330–332 (in Russian). https://elibrary.ru/fqdasg
12. Petrov V.V., Belko A.A., Matsinovich M.S., Romanova E.V., Novikov E.A. Effectiveness of the tablets “Cardiosafe 5 mg” for heart failure caused by chronic degeneration of heart valves in dogs and dilated cardiomyopathy (results of clinical studies). Veterinarnyy zhurnal Belarusi. 2022; (2): 46–49 (in Russian). https://elibrary.ru/jvotty
13. Badova O.V., Lebedeva A.L., Tagirova L.R. Influence of early clinical diagnostics of dilated cardiomyopathy in doberman dogs on the course of pathology. Vestnik Chuvash State Agricultural Academy. 2020; (4): 31–36 (in Russian). https://elibrary.ru/fzeqwa
14. Druzhinina V.S., Boev V.I., Morozov I.A. Features of diagnosis and therapy of dogs with dilated cardiomyopathy. Collection of scientific papers of the Twelfth International interuniversity conference on clinical veterinary medicine in the Partners format. Moscow: Sel’skokhozyaystvennyye tekhnologii. 2022; 389–398 (in Russian). https://elibrary.ru/wymmhe
15. Nazarova M.V. Use of pimobendan (Vetmedin ® ) in clinical practice for mitral valve endocardiosis. VetPharma. 2016; (4): 60–63 (in Russian). https://elibrary.ru/wnhzon
Review
For citations:
Golovin V.V., Abramov S.V., Balyshev A.V., Kochetkov P.P., Violin B.V. Study of the bioequivalence of drugs for veterinary use «Avecardit» and «Vetmedin S» in the body of dogs. Agrarian science. 2024;(6):33-38. (In Russ.) https://doi.org/10.32634/0869-8155-2024-383-6-33-38